{"entity":{"id":"astellas","kind":"company","name":"Astellas","aka":["OSI Pharmaceuticals"],"tldr":"Astellas co-owns Padcev and makes Vyloy, the first Claudin 18.2 drug.","summary":"Astellas, based in Tokyo and listed as 4503.T, co-owns Padcev with Pfizer and makes Vyloy, or zolbetuximab, the first Claudin 18.2 drug, approved in 2024. Its oncology portfolio also includes enzalutamide, shared with Pfizer, and gilteritinib for FLT3-mutated acute myeloid leukaemia, and OnCo links it to the EV-302 paper that made enfortumab vedotin plus pembrolizumab the first-line standard in advanced bladder cancer, to SPOTLIGHT for zolbetuximab in gastric cancer and to ADMIRAL for gilteritinib. Its cancer pages cover bladder, gastric, prostate and acute myeloid leukaemia. Whether Claudin 18.2 becomes a broad target class, with ADCs and CAR-Ts following the antibody, is the question zolbetuximab opened. Enfortumab vedotin has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Astellas_Pharma","links":[{"label":"Official website","url":"https://www.astellas.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","setidegrasib","asp2138","xnw27011"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04076059","nct02960022","nct07005154","nct06792435","nct07488676","nct06901531","nct03816163","nct07475806","nct07421700","nct07566156","nct04821622","nct03505320","nct04225117","nct05520567","spotlight-glow","nct07730021","nct03182244","nct07287995"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.astellas.com","ticker":"4503.T","investors":[],"funding":[]},"route":"/companies/astellas/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/"},{"id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/"},{"id":"xnw27011","kind":"drug","name":"XNW27011","route":"/drugs/xnw27011/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"trial":[{"id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/"},{"id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/"},{"id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/"},{"id":"nct03182244","kind":"trial","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","route":"/trials/nct03182244/"},{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/"},{"id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/"},{"id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/"},{"id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/"},{"id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/"},{"id":"nct03816163","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","route":"/trials/nct03816163/"},{"id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/"},{"id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/"},{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/"},{"id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/"},{"id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/"},{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/"},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/"},{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/"},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/"},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/"},{"id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/"},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/"},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/"},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/"},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/"},{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/"},{"id":"nct06553885","kind":"trial","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","route":"/trials/nct06553885/"},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/"},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/"},{"id":"nct04821622","kind":"trial","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","route":"/trials/nct04821622/"},{"id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/"},{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"paper":[{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/"},{"id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/"},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/"},{"id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/"},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"}],"technology":[{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/"}]}}